レンボレキサント
doi:10.5664/jcsm.6800. PMC 5656478. PMID 29065953. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656478/.
“Concentration-Response Modeling of ECG Data From Early-Phase Clinical Studies as an Alternative Clinical and Regulatory Approach to Assessing QT Risk - Experience From the Development Program of Lemborexant”. J Clin Pharmacol 57 (1): 96–104. (January 2017). doi:10.1002/jcph.785. PMID 27338807.